TOP
Skip to the content
THANC Foundation
    • About Us
          • Board of Directors
          • Staff
          • Contact Us
          • Financials
            • Form 990 (2021)
            • Form 990 (2020)
            • Form 990 (2019)
          • Press Materials
            • Donor Privacy Policy
          • 2022 Year in Review
          • News
          • Events
          • 30 Stories in 30 Days™
            • Share Your Story
          • Faces of Courage™
          • Videos
          • Photo Gallery
    • Our Mission
          • For Patients
            • The Cancer Journey
            • Eating Healthy & Treating Cancer
            • Prevention Starts with #BetterHabits
            • FAQs
            • Resources
            • SPOHNC
          • EL-PFDD: Xerostomia
            • Xerostomia - Voice of the Patient Report
            • Xerostomia - Online Comments
            • Xerostomia EL-PFDD Meeting Info
          • Research
            • Research List
            • Head & Neck Articles
            • Thyroid Articles
            • Transoral Robotic Surgery (TORS)
          • Join Our Team
            • Fellows
            • Research Associates
            • Gutierrez Scholar
            • Observers
            • OMFS Residency Program
          • Major Initiatives
            • THANC Guide
            • TIRO
          • THANC’s Mission

          • We are committed to supporting research and education in the early detection and treatment of thyroid and head and neck cancer; to advancing new therapeutic approaches; and to alleviating the suffering and functional impairment of patients who undergo treatment.

    • Shop
    • Give Today
          • Give Your Change
          • Connect a card to round-up your purchases to the next dollar and donate your change.

          • Donate Now
          • By making a donation today, you can help us do more with our research and reach further with our online resources.

          • Donate Monthly
          • For as little as $10 a month, you can become a sustaining member of research and fund the future of medicine.

          • The THANC Foundation is a 501(c)(3) non-profit organization (Federal Tax ID 80-0062118). Your contribution will be tax-deductible under the fullest extent of the law.

          • Start a Fundraiser
          • Browse Fundraisers
          • Account Login
          • 9 Ways to Support THANC
            • 3 Steps to Create a Fundraiser
            • Make THANC Your GoodShop Charity
            • Estate Planning
    • About Us
          • Board of Directors
          • Staff
          • Contact Us
          • Financials
            • Form 990 (2021)
            • Form 990 (2020)
            • Form 990 (2019)
          • Press Materials
            • Donor Privacy Policy
          • 2022 Year in Review
          • News
          • Events
          • 30 Stories in 30 Days™
            • Share Your Story
          • Faces of Courage™
          • Videos
          • Photo Gallery
    • Our Mission
          • For Patients
            • The Cancer Journey
            • Eating Healthy & Treating Cancer
            • Prevention Starts with #BetterHabits
            • FAQs
            • Resources
            • SPOHNC
          • EL-PFDD: Xerostomia
            • Xerostomia - Voice of the Patient Report
            • Xerostomia - Online Comments
            • Xerostomia EL-PFDD Meeting Info
          • Research
            • Research List
            • Head & Neck Articles
            • Thyroid Articles
            • Transoral Robotic Surgery (TORS)
          • Join Our Team
            • Fellows
            • Research Associates
            • Gutierrez Scholar
            • Observers
            • OMFS Residency Program
          • Major Initiatives
            • THANC Guide
            • TIRO
          • THANC’s Mission

          • We are committed to supporting research and education in the early detection and treatment of thyroid and head and neck cancer; to advancing new therapeutic approaches; and to alleviating the suffering and functional impairment of patients who undergo treatment.

    • Shop
    • Give Today
          • Give Your Change
          • Connect a card to round-up your purchases to the next dollar and donate your change.

          • Donate Now
          • By making a donation today, you can help us do more with our research and reach further with our online resources.

          • Donate Monthly
          • For as little as $10 a month, you can become a sustaining member of research and fund the future of medicine.

          • The THANC Foundation is a 501(c)(3) non-profit organization (Federal Tax ID 80-0062118). Your contribution will be tax-deductible under the fullest extent of the law.

          • Start a Fundraiser
          • Browse Fundraisers
          • Account Login
          • 9 Ways to Support THANC
            • 3 Steps to Create a Fundraiser
            • Make THANC Your GoodShop Charity
            • Estate Planning

Clinical Trial Finder

Search Results

A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

Study Purpose

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Males and females ≥ 18 years of age. 2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. 3. Acceptable bone marrow and organ function at screening as described below: 1. ANC ≥ 1500/μL (without WBC growth factor support) 2. Platelet count ≥ 100,000/μL without transfusion support. 3. Hemoglobin ≥ 9 g/dL (Transfusion is allowed to achieve this Hb) 4. Total Bilirubin ≤ 1.5 x ULN; (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN) 5. AST (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases) 6. ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases) 7. Creatinine clearance (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula). 4. Ability to swallow and retain oral medications. 5. Histopathological diagnosis of a solid tumor. Note: The solid tumors must be in Stage IV at screening. 6. Evidence of measurable disease per RECIST, v1.1 for solid tumors. 7. Standard curative measures do not exist, and the patient must have exhausted all effective therapies available locally. Notes: 7a. At a minimum, solid tumor patients must have received at least two lines of systemic therapies in the metastatic incurable settings (these two lines must be in the metastatic setting and not in the earlier stage of cancer). 7b. Any cancer patient with access to any effective therapy must not be enrolled.

Exclusion Criteria:

1. Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from Cycle 1 Day 1 of the study. Note: Concomitant use of low-dose prednisone (up to 10 mg/day) or medroxyprogesterone is allowed. Note: Patients with CRPC (castrate-resistant prostate cancer) should continue to receive ongoing medical castration with LHRH analogs, and such patients are allowed. 2. Presence of acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by NCI CTCAE v 5.0. 3. Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial) • Use of any investigational agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1. 4. Use of drugs which are moderate / strong CYP3A4 inducers and/or drugs which are predominantly metabolized by CYP3A4 within 1week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1. • Note: This class of drugs are also prohibited during DLT evaluation period and must be either avoided or used with caution beyond DLT evaluation period. 5. Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) metastases. Patients with previously treated (> 6 months of screening) CNS metastases and are now stable and asymptomatic, from CNS perspective, are allowed. 6. Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia). 7. Patients with leukemia, myelodysplastic syndrome, multiple myeloma, or lymphoma. 8. Active infection requiring systemic therapy. Note: Prophylactic use of antibiotics is allowed. Any infection detected during the screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed. 9. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness. 10. Known active or chronic hepatitis B (HBsAg +ve) or hepatitis C infection (HCV antibody +ve). 11. The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study. 12. Uncontrolled congestive heart failure (New York Heart Association [NYHA] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or transient ischemic attack, or pulmonary embolism within 3 months prior to Cycle 1 Day 1. 13. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in the past 3 months, before Cycle 1 Day 1. 14. QTc (Bazzett) interval >460 ms on ECG at screening and/or at Cycle 1 Day 1 pre-dose. 15. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g., renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or clinically significant laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study. 16. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of the person(s) with confirmed Covid-19 infection, at screening or Day 1 of Cycle 1. 17. Positive pregnancy test for women of childbearing potential (WOCBP) at the screening or enrolment visit. 18. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable contraceptive methods. (hormonal contraceptive, IUD, or any double combination of the male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05865002
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Aurigene Discovery Technologies Limited
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Akhil Kumar
Principal Investigator Affiliation Aurigene Oncology Limited
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries India
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Relapsed Malignant Solid Neoplasm
Additional Details

This is a Phase I, Open Label, Dose-Escalation, First-in-Human study in adult patients with select relapsed advanced malignancies. The safety and tolerability of oral AUR107 will be evaluated in patients with selected advanced solid tumors (Non-small cell lung cancer, Gastric cancer, Urothelial cancer, Kidney cancer, Colon cancer, and Esophageal cancer) who do not have any available curative or life-prolonging treatment options and have exhausted all effective locally available therapies. The traditional 3+3 design for dose escalation will be used to evaluate the safety, pharmacokinetics/pharmacodynamics, and determine the Optimal Biological Dose of AUR107 as a single agent. The Optimal Biological Dose will be selected using a totality of safety, PK, and PD data.

Arms & Interventions

Arms

Experimental: AUR107, 5mg to 200mg

Currently, planned dose levels are 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD, 90 mg QD, 135 mg QD, and 200 mg QD

Interventions

Drug: - AUR107

Once daily

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

HCG City Cancer Centre, Vijayawada, Andhra Pradesh, India

Status

Not yet recruiting

Address

HCG City Cancer Centre

Vijayawada, Andhra Pradesh, 520002

Site Contact

Dr Lakshmi Priyadarshini

[email protected]

+91 9966030988

Omega Hospital, Visakhapatnam, Andhra Pradesh, India

Status

Recruiting

Address

Omega Hospital

Visakhapatnam, Andhra Pradesh, 530040

Site Contact

Dr. Bellala Ravishankar

[email protected]

+91 9849123256

Surat, Gujarat, India

Status

Recruiting

Address

Unique Hospital Multispeciality and Research Institute

Surat, Gujarat, 395002

Site Contact

Dr. Ankit Patel

[email protected]

+91 9825404202

Bangalore, Karnataka, India

Status

Recruiting

Address

Vydehi Institute of Medical Sciences and Research Centre

Bangalore, Karnataka, 560066

Site Contact

Shashidhar V Karpurmath, MBBS

[email protected]

8861085629

K R Hospital, Mysore, Karnataka, India

Status

Recruiting

Address

K R Hospital

Mysore, Karnataka, 570001

Site Contact

Dr. Mukesh S

[email protected]

+91 9886873788

Pune, Maharashtra, India

Status

Recruiting

Address

Grant Medical Foundation Ruby Hall Clinic

Pune, Maharashtra, 411001

Site Contact

Dr. Minish Jain

[email protected]

+91 9823133390

Krupamayi Hospital, Aurangabad, Maharastra, India

Status

Recruiting

Address

Krupamayi Hospital

Aurangabad, Maharastra, 431001

Site Contact

Dr Viraj Vijay Borgaonkar

[email protected]

+91 9673073555

All India Institute of Medical Sciences, New Delhi, India

Status

Recruiting

Address

All India Institute of Medical Sciences

New Delhi, , 110029

Site Contact

Dr. Deepam Pushpam

[email protected]

+91 9650629370

Resources

This is placeholder for the THANC Foundation to update

Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with a healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with site contacts or other relevant parties. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage trial participants to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

The THANC Foundation is a 501(c)(3) charitable organization.

Federal Tax ID 80-0062118.

Follow us on Social Media

THANC’s Mission

We are committed to supporting research and education in the early detection and treatment of thyroid and head and neck cancer; to advancing new therapeutic approaches; and to alleviating the suffering and functional impairment of patients who undergo treatment.

Copyright © 2023 THANC Foundation

  • Donate
  • Login
  • About THANC
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • THANC Guide
  • TIRO
This website uses cookies to ensure you get the best experience on our website. Learn moreGot it!
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Cookie Duration Description
CONSENT 16 years 4 months 21 days 7 hours 17 minutes These cookies are set via embedded youtube-videos. They register anonymous statistical data on for example how many times the video is displayed and what settings are used for playback.No sensitive data is collected unless you log in to your google account, in that case your choices are linked with your account, for example if you click “like” on a video.
vuid 2 years This domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.
_ga 2 years This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-26689388-1 1 minute This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.
_gid 1 day This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Cookie Duration Description
IDE 1 year 24 days Used by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
test_cookie 15 minutes This cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
VISITOR_INFO1_LIVE 5 months 27 days This cookie is set by Youtube. Used to track the information of the embedded YouTube videos on a website.
YSC session This cookies is set by Youtube and is used to track the views of embedded videos.
yt-remote-connected-devices never These cookies are set via embedded youtube-videos.
yt-remote-device-id never These cookies are set via embedded youtube-videos.
yt.innertube::nextId never These cookies are set via embedded youtube-videos.
yt.innertube::requests never These cookies are set via embedded youtube-videos.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Cookie Duration Description
charitable_session 1 day No description available.
cookielawinfo-checkbox-functional 1 year The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
debug never No description available.
socialsnap_viewed_1052 session No description
socialsnap_viewed_1057 session No description
socialsnap_viewed_1205 session No description
socialsnap_viewed_1253 session No description
socialsnap_viewed_1294 session No description
socialsnap_viewed_13 session No description
socialsnap_viewed_1374 session No description
socialsnap_viewed_177 session No description
socialsnap_viewed_1888 session No description
socialsnap_viewed_1889 session No description
socialsnap_viewed_1890 session No description
socialsnap_viewed_1958 session No description
socialsnap_viewed_201 session No description
socialsnap_viewed_205 session No description
socialsnap_viewed_207 session No description
socialsnap_viewed_209 session No description
socialsnap_viewed_211 session No description
socialsnap_viewed_213 session No description
socialsnap_viewed_217 session No description
socialsnap_viewed_2195 session No description
socialsnap_viewed_2197 session No description
socialsnap_viewed_2199 session No description
socialsnap_viewed_2201 session No description
socialsnap_viewed_2203 session No description
socialsnap_viewed_2205 session No description
socialsnap_viewed_2207 session No description
socialsnap_viewed_221 session No description
socialsnap_viewed_2227 session No description
socialsnap_viewed_225 session No description
socialsnap_viewed_227 session No description
socialsnap_viewed_2353 session No description
socialsnap_viewed_26 session No description
socialsnap_viewed_2654 session No description
socialsnap_viewed_2656 session No description
socialsnap_viewed_2659 session No description
socialsnap_viewed_2678 session No description
socialsnap_viewed_271 session No description
socialsnap_viewed_2796 session No description
socialsnap_viewed_293 session No description
socialsnap_viewed_3022 session No description
socialsnap_viewed_305 session No description
socialsnap_viewed_307 session No description
socialsnap_viewed_3071 session No description
socialsnap_viewed_309 session No description
socialsnap_viewed_31 session No description available.
socialsnap_viewed_3121 session No description
socialsnap_viewed_33 session No description
SAVE & ACCEPT
Powered by CookieYes Logo